Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report. (28th August 2021)

• Record Type: Journal Article
• Authors: Adeel, Alina; Qu, Ming D; Siddiqui, Efaza; Levitz, Stuart M; Ellison, Richard T
• Is Part Of: Open forum infectious diseases. Volume 8:Number 11(2021)
• Publication Date: 2021-08-28
• Subjects: antifungal -- echinocandin -- multidrug-resistant fungal infection -- rezafungin; Communicable diseases -- Periodicals; Medical microbiology -- Periodicals; Infection -- Periodicals; 616.9
• DOI: 10.1093/ofid/ofab431
• Languages: English
• ISSNs: 2328-8957

Abstract

Abstract: Rezafungin is a semisynthetic, long-acting echinocandin with broad-spectrum activity against many Candida species and Aspergillus species, including a subset of drug-resistant strains. It is currently in phase III trials and was found to be safe and effective for the treatment of candidemia and/or invasive Candida infections in a phase II trial. However, there are no long-term safety or efficacy data. We report on the successful ongoing compassionate use of rezafungin obtained through expanded access for over 1 year in a patient with a multidrug-resistant Candida glabrata mediastinal infection from a vascular graft infection and retained foreign material.